Veracyte (NASDAQ:VCYT) & CannLabs (OTCMKTS:CANL) Critical Survey
2025-04-26T05:44:47Z
Veracyte (NASDAQ:VCYT – Get Free Report) and CannLabs (OTCMKTS:CANL – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation,…
Veracyte (NASDAQ:VCYT – Get Free Report) and CannLabs (OTCMKTS:CANL – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, analyst recommendations and earnings.
Earnings & Valuation
This table compares Veracyte and CannLabs”s revenue, earnings per share and valuation.
Get Veracyte alerts:
Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veracyte $445.76 million 5.64 -$74.40 million $0.30 107.43 CannLabs N/A N/A N/A N/A N/A
CannLabs has lower revenue, but higher earnings than Veracyte.
Profitability
Net Margins Return on Equity Return on Assets Veracyte -2.18% 3.02% 2.80% CannLabs N/A N/A N/A
Risk & Volatility
This table compares Veracyte and CannLabs’ net margins, return on equity and return on assets.
Veracyte has a beta of 2.03, indicating that its share price is 103% more volatile than the S&P 500. Comparatively, CannLabs has a beta of 1.52, indicating that its share price is 52% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current ratings for Veracyte and CannLabs, as provided by MarketBeat.
Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Veracyte 1 1 8 0 2.70 CannLabs 0 0 0 0 0.00
Veracyte currently has a consensus target price of $42.60, suggesting a potential upside of 32.17%. Given Veracyte’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Veracyte is more favorable than CannLabs.
Summary
Veracyte beats CannLabs on 7 of the 8 factors compared between the two stocks.
About Veracyte
(Get Free Report)
Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm’s portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.
About CannLabs
(Get Free Report)
CannLabs, Inc. provides cannabis testing laboratory services in the United States. Its testing services include potency testing, residual solvent analysis, microbiological testing, pesticide testing, heavy metals testing, nutrient analysis, terpenes analysis, shelf-life/stability studies, gene expression testing, and genotyping/phenotyping testing. The company also offers data/analytics and consulting, as well as education services. CannLabs, Inc. was incorporated in 2010 and is based in Denver, Colorado.
Receive News & Ratings for Veracyte Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Veracyte and related companies with MarketBeat.com’s FREE daily email newsletter.
Auto-posted from news source
About The Author
